"In the first quarter of fiscal year 2009, our organic growth from existing core products and new products launched in fiscal year 2008 demonstrates the success of our growth strategy. We received two approvals from the Chinese SFDA to produce Laonian Kechuan Tablets and Fuke Zhidai Tablets. We plan to launch these two drugs before the end of 2008 and we are optimistic that these new drugs will further improve our profitability and be additional growth contributors to our top-line and bottom-line numbers. We will continue to focus on broadening our product portfolio, increasing our sales and marketing activities, and further expanding our distribution network. Our extensive market research provides evidence that we are well positioned in the Chinese pharmaceutical industry, the benefit of which will continue to support our revenue and net income growth throughout fiscal 2009 and beyond," concluded Dr. Jiang.
The Company will host a conference call to discuss the 2009 first quarter financial results on Tuesday, November 11, 2008 at 8:30 a.m. EST. Interested participants should call 800-762-8795 within the United States, or US +1-480- 629-9031 if calling internationally. The conference ID is 3940851. It is advisable to dial in approximately 5-10 minutes prior to 8:30 a.m. EST. If you are unable to participate in the call at the scheduled time, a playback will be available on Tuesday, November 11, 2008 at 11:30 a.m. ET through Thursday, November 27, 2008 at 11:59 p.m. ET. To listen to the playback, please call 800-406-7325 from within the United States, or US +1 303-590-3030 internationally. Please use pass code 3940851 for the replay.
About Tianyin Pharm
|SOURCE Tianyin Pharmaceutical Co., Inc.|
Copyright©2008 PR Newswire.
All rights reserved